ONCODESIGN PM overview

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, today announced the results of its annual General Meeting, which took place at 2:30pm on 30 May 2023, and the nomination of Florence Dupré as a member of its Board of Directors. Karine Lignel, Deputy CEO and COO, said : "I am very pleased with the way that OPM's first annual General...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its 2022 financial results. Philippe GENNE, Chief Executive Officer of Oncodesign, said: "OPM officially started its activity in September 2022 following the split with Oncodesign Biotechnology SA, and was listed on Euronext Growth in December by successfully raising €8 million...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM) (Paris:ALOPM), a clinical stage biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the clinical entry of its drug candidate ODS-101 with the first subject dosing in Phase 1 clinical trial in healthy volunteers. Philippe Genne, Chairman and CEO of OPM, commented : " This is a very important milestone for Oncodesign Precision...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM) (Paris:ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today publishes its indicative financial calendar for 2023. Event Date* 2022 Annual Results April 4, 2023 Annual General Meeting May 30, 2023 2023 First Half Results September 19, 2023 *subject to modification. Publication after financial market close. About Oncodesign...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Servier, an international pharmaceutical company, announce the creation of FederAidd ( Federation for Artificial Intelligence in Drug Discovery ), an international open innovation virtual campus whose objective is to make the drug discovery process (or Drug Discovery "DD") more...